Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.

A Survey of Patients With Elevated Serum IGG4 With Unknown IGG4-related Disease to Whom Biopsy and Performance of Subsequent Specific Staining for Clinical, Laboratory and Pathologic Correlation.

Sponsors

Lead Sponsor: Meir Medical Center

Source Meir Medical Center
Brief Summary

Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features. Histopathological analysis of biopsy specimens remains the cornerstone in the diagnosis of IgG4- related disease. Elevated concentrations of IgG4 in tissue and serum are helpful in diagnosing IgG4-related disease, but neither one is a specific diagnostic marker. Correlation with specific histopathological findings is essential, regardless of the serum IgG4 concentration, the number of IgG4-positive plasma cells in tissue, or the ratio of IgG4 to IgG in tissue. Misdiagnoses of IgG4-related disease are increasingly common because of excessive emphasis on moderate elevations of serum IgG4 concentration and overreliance on the finding of IgG4-positive plasma cells in tissue.

Detailed Description

IgG4 is a unique antibody in both structure and function. This molecule accounts for less than 5% of the total IgG in healthy persons and is the least abundant IgG subclass. In contrast to IgG1, IgG2, and IgG3, serum IgG4 concentrations among ostensibly healthy people vary by a factor of more than 100 (normal range, 0.01 to 1.4 mg per milliliter), but IgG4 concentrations within individual persons are generally stable. Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features. These different conditions were previously thought to be unrelated [2-4]. The commonly shared features include tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis that has a characteristic "storiform" pattern. In addition, elevated serum concentrations of IgG4 are found in 60 to 70 percent of patients with IgG4-RD. Two major presentations of this condition, which often affects more than one organ, are type 1 autoimmune pancreatitis (IgG4-related pancreatitis) and salivary gland disease; the later may present as salivary gland enlargement or as sclerosing sialadenitis (formerly termed "Mikulicz disease" and Küttner's tumor, respectively). These conditions often resemble Sjögren's syndrome but are pathophysiologically distinct from this disorder. The preferred name for the overall condition is IgG4-related disease. The presence of IgG4-bearing plasma cells is required for a diagnosis of IgG4- related disease, but IgG4-positive cells are found in a wide variety of inflammatory infiltrates, and the detection of substantial numbers of IgG4- positive plasma cells is therefore not diagnostic of IgG4-related disease. Tissues from patients with IgG4-related disease show diffuse infiltrates of IgG4-bearing plasma cells, in contrast to the focal aggregates of IgG4-bearing cells that are detected in most other inflammatory mimickers of this condition. A diffuse plasma-cell infiltrate with more than 30 IgG4-positive cells per high power field and a ratio of IgG4 to IgG that is higher than 50% provides compelling evidence of IgG4-related disease. The study will examine the clinical data from the computerized database of Meir Hospital for patient with unknown IGG4-related disease with high serum levels of IGG4 that were admitted for hospitalization for any reason in a period of 14 years, from January 2000 to June 2014. Since biopsy has proven to be the hallmark in diagnosing IGG4 RD, we decided to complete the investigation in a pool of patients to whom high IGG4 serum levels where confirmed and to whom biopsies from any suitable tissue where obtained for other reasons than IGG4 RD and then to perform specific staining for IGG4 to those samples, by sending them back to the pathology service at our hospital. Furthermore clinical and other laboratory features of each positive patient will then be correlated from the history of admission of each patient.

Overall Status Completed
Start Date 2014-10-01
Completion Date 2015-09-01
Primary Completion Date 2015-09-01
Study Type Observational
Primary Outcome
Measure Time Frame
serum level of IGG4 6 months
Secondary Outcome
Measure Time Frame
specific staining for IGG4 to biopsy samples six months
Enrollment 11
Condition
Eligibility

Sampling Method:

Probability Sample

Criteria:

Inclusion Criteria: - All patients that where admitted during the period of January 2000 to June 2014 at MEIR HOSPITAL KFAR SAVA, with at least one result of a high serum level of IGG4 according to the accepted normal range in our laboratory (more than 100mg/dL) and to whom biopsy of a suitable tissue was obtained for other reasons than IGG4 Related Diseases. - Both genders will be included. - Patients of all ages. Exclusion Criteria: - Patients who have already been diagnosed with IGG4-Related Diseases.

Gender:

All

Minimum Age:

N/A

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Location
Facility: Meir Medical Center
Location Countries

Israel

Verification Date

2014-08-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Meir Medical Center

Investigator Full Name: yair levy

Investigator Title: Meir Medical Center

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Label: IgG4 UKN diagnosis

Description: who ever been found with IgG4 sub class in blood sample or in his byposy

Study Design Info

Observational Model: Case-Only

Time Perspective: Retrospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News